## Edgar Filing: MUEHL DANIEL W - Form 4

Check this box if no longer subject to Section 16.       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       OMB Number Expires         STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES       Expires Estimation burder								OMB Number: Expires: Estimated a burden hou response			
MUEHL DANIEL W Syr			Symbol	2. Issuer Name <b>and</b> Ticker or Trading Symbol Clovis Oncology, Inc. [CLVS]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Mo			(Month/D	<ul><li>3. Date of Earliest Transaction</li><li>(Month/Day/Year)</li><li>03/01/2018</li></ul>				Director 10% Owner Officer (give title Other (specify below) See Remarks			
				mendment, Date Original Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction (Month/Day/Y	ear) Executio any		3. Transactic Code (Instr. 8) Code V	(Instr. 3,	spose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	03/01/2018			M	547	(D) A	<u>(1)</u>	3,163	D		
Common Stock	03/01/2018			F	259	D	\$ 55.51	2,904	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: MUEHL DANIEL W - Form 4

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	Derivative	6. Date Exercisable and Expiration Date (Month/Day/Year)		(Instr. 3 and 4)		8. Price Derivat Securit (Instr. 5
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units	<u>(1)</u>	03/01/2018(2)		М	547	(2)	(2)	Common Stock	547	\$ 0

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
MUEHL DANIEL W C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER, CO 80301			See Remarks			
Signatures						

/s/ Daniel W. 03/02/2018 Muehl

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- On August 25, 2016, the reporting person was granted 8,750 Restricted Stock Units. 25% of such Restricted Stock Units vested on (2)August 25, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

## **Remarks:**

### Senior Vice President of Finance, Principal Financial Officer and Principal Accounting Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.